The Institute of Human Virology, Nigeria (IHVN), through its International Research Center of Excellence, has been lauded as a leader in addressing some of the country’s most critical health challenges, including HIV, tuberculosis (TB) and other infectious diseases.
Over the past 20 years, the institute has led the improvement of Nigeria’s public health system through strategic partnerships, capacity building and cutting-edge research.
Speaking at a press briefing in Abuja to commemorate two decades of excellence in public health, the executive director of IHVN, Prof. Alash’le Abimiku emphasised the institute’s focus on fostering local healthcare solutions. She noted that since its inception, IHVN has worked to strengthen Nigeria’s healthcare infrastructure by collaborating with both local and international partners.
“Our collaboration with global health organizations has been crucial in building a solid foundation for healthcare delivery in Nigeria,” Abimiku said, citing the involvement of HIV discoverer Robert Gallo, who helped establish early services and capacity-building efforts in Nigeria.
IHVN’s comprehensive approach to healthcare has resulted in the establishment of specialised facilities to handle complex health issues, such as Nigeria’s first Biosafety Level 3 laboratory at the National TB Reference Centre in Zaria. This laboratory is key in combating drug-resistant strains of tuberculosis, including extensively drug-resistant TB (XDR TB).
“We train healthcare professionals to monitor and control the spread of these extremely resistant forms of TB, safeguarding public health,” Abimiku added.
In addition to its work in HIV and TB, IHVN has been at the forefront of developing diagnostic methods tailored for pediatric populations. Recognising the unique challenges in diagnosing infections in infants, the institute has focused on refining techniques to improve early detection in children.
The COVID-19 pandemic highlighted the importance of monitoring circulating pathogens, a strategy IHVN has been deeply involved in. Abimiku noted that the institute is working on tracking pathogens to prepare for potential outbreaks in Nigeria and West Africa.
Perhaps one of IHVN’s most groundbreaking achievements is its participation in HIV vaccine research. Nigeria is the only country in West Africa involved in this critical global health initiative. “We are currently working to identify an effective HIV vaccine tailored to the strains prevalent in our region,” she said, underscoring the importance of localised solutions in addressing global health challenges.
Beyond infectious diseases, IHVN is also focused on non-communicable diseases (NCDs) such as diabetes and cardiovascular diseases, which are becoming more common among younger populations in Nigeria. Abimiku expressed concern over this trend, calling for comprehensive health solutions that address all aspects of patient care.
“Young people are increasingly affected by these health challenges, and our research indicates that we need to prioritise preventive and long-term care strategies,” she said.
IHVN’s ongoing research efforts also include studies on sickle cell disease and various types of cancer. The institute is part of an international network testing new drugs and therapies to ensure that research findings translate into actionable health policies.
Abimiku stressed the importance of collaboration with both government agencies and international organisations to ensure sustainable improvements in Nigeria’s healthcare system. “We are committed to supporting the government’s efforts in public health and contributing to the country’s healthcare agenda,” she said.
Since its establishment in 2004, IHVN has achieved significant milestones, including providing HIV testing services to over 18 million people and administering life-saving antiretroviral treatment to more than 600,000 individuals. Additionally, the institute has trained over 50,000 healthcare workers and provided TB services to more than 300,000 people.
The institute was initially founded with a grant from Professor William Blattner, then director of the epidemiology division at the University of Maryland’s Institute of Human Virology. The goal was to build a sustainable public health infrastructure to address the HIV/AIDS crisis in Nigeria. Over time, IHVN expanded its services to tackle other infectious and non-infectious diseases.
Today, IHVN operates under the guidance of a Board of Directors that includes professionals and leaders from various fields, including health, research, management, and finance. The institute’s mission remains focused on providing quality health services, conducting impactful research and building capacity for sustainable healthcare delivery in Nigeria.
Reflecting on the institute’s 20-year journey, Abimiku expressed gratitude to IHVN’s staff, the University of Maryland, and the many stakeholders and partners who have contributed to its success. “Our achievements are a testament to the power of collaboration and the shared commitment to improving the lives of Nigerians,” she said.
As IHVN looks to the future, the institute remains dedicated to addressing the evolving health needs of Nigeria and West Africa. It continues to call for stronger partnerships with both public and private sectors to tackle the region’s growing health challenges.
